Overview

A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

Status:
Completed
Trial end date:
2021-02-21
Target enrollment:
Participant gender:
Summary
This is a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 versus placebo as measured by infectious virus detection in symptomatic adult outpatients with COVID-19
Phase:
Phase 2
Details
Lead Sponsor:
Ridgeback Biotherapeutics, LP